Tetsuya Terasaki, PhD

Tetsuya Terasaki

Professor, Division of Membrane Transport and Drug Targeting, Department of Biochemical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences

Education and Career

  • Ph.D., in Biopharmacy (University of Tokyo), 1982
  • Assistant Professor, Kanazawa University, UCLA Visiting Assistant Fellow, 1985
  • Associate Professor, University of Tokyo, 1992
  • Professor, Tohoku University, 1996
  • Distinguished Professor, Tohoku University, 2008


  • Targeted absolute proteomics for the protein network related to drug sensitivity
  • In the development of safe and effective chemotherapy, it is an important subject to clarify the protein network related to drug sensitivity and resistant. To solve this subject, we have developed a highly sensitive and simultaneous quantification method for multiple proteins, which is functionally important. The principle of the quantification is to determine and quantify the trypsin digested peptide fragments of each target protein by LC-MS/MS. As the MS signal varied around 106-folds among peptide fragments, the most important issue is how to select an appropriate peptide exhibiting greater MS signal. We have developed an in silico selection criteria for the peptide fragments for quantification among the trypsin-digested peptide fragments derived from target proteins. Moreover, the presently developed method enables us to quantify the plasma membrane proteins, which was not possible to be quantified by the previous methods to date. The purpose of the present study is to clarify the mechanism of drug sensitivity and resistant based on the quantitative analysis of the protein network relating to drug sensitivity and resistant such as membrane transporters, enzymes, receptors and channels among several cells exhibiting the differential drug sensitivity. We will facilitate the collaboration with the researchers having different background and would develop a rational chemotherapy and effective drug-delivery overcoming drug-resistant mechanism in target cells based on the information of absolute expression profile of proteins; that is pharmacoproteomics.

Award and publication

  1. Ebert Prize from American Pharmaceutical Association, 1985
  2. American Association of Pharmaceutical Scientists, Fellow, 2004
  3. The Academy of Pharmaceutical Science and Technology, Japan Award, 2007
  4. The Japanese Society for the Study of Xenobiotics Award, 2007
  5. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, Terasaki T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res., 25, 1469-1483 (2008)


  • terasaki[atmark]


Page Top

Site Navigation


  • HOME
  • Contact,Access
  • Greeting
  • What is Network Medicine?
  • Mission and Design
  • Implementations
  • Investigators
  • Events
  • Fellowship Program
Tohoku University Global COE for Conquest of Signal Transduction Diseases with Network Medicine